Prevenar joins schedule in June

Reid, Stewart
May 2008
New Zealand Doctor;5/7/2008, p17
The article focuses on the use of Prevenar as vaccine. According to the author, starting June 1, 2008 heptavalent conjugate pneumococcal vaccine Prevenar will be part of the New Zealand routine immunization schedule. The immunization will have a four-dose schedule with doses at six weeks, three, five, and 15 months. Prevenar has seven serotypes including 4, 6B, 9V, 14, 18C, 19F, and 23F and also contains 16µg of type 6B and 2µg of the other six types.


Related Articles

  • Pneumococcal Immunization: From Policy to Practice. Schwartz, Benjamin; Breiman, Robert F. // JAMA: Journal of the American Medical Association;9/5/90, Vol. 264 Issue 9, p1154 

    Editorial. Deals with the low utilization of pneumococcal vaccines targeted for adults in the U.S. Factors behind the lack of use of pneumococcal vaccines; Strategies that can be adopted to increase utilization of pneumococcal vaccines; Cost benefits of immunization.

  • New children's vaccines, new direction. Kassianos, George // GP: General Practitioner;1/12/2007, p30 

    The article focuses on issues related to the introduction of routine immunization of infants against pneumococcal disease in Great Britain. The new immunization schedule was announced on June 12, 2006. One of the problems of introducing a new vaccine is how to fit another vaccine into the...

  • General considerations.  // WHO Technical Report Series;2004, Issue 927, p66 

    The article focuses on polysaccharide vaccines for infections caused by Streptococcus pneumoniae, which are responsible for substantial morbidity and mortality, commonly on children and the elderly. Pneumociccus are classified based on chemical and serological distinct capsular polysaccharides....

  • Differential Effects of Pneumococcal Vaccines against Serotypes 6A and 6C. Park, In H.; Moore, Matthew R.; Treanor, John J.; Pelton, Stephen I.; Pilishvili, Tamara; Beall, Bernard; Shelly, Mark A.; Mahon, Barbara E.; Nahm, Moon H. // Journal of Infectious Diseases;12/15/2008, Vol. 198 Issue 12, p1818 

    Background. Because classic pneumococcal serotyping methods cannot distinguish between serotypes 6A and 6C, the effects of pneumococcal vaccines against serotype 6C are unknown. Pneumococcal vaccines contain serotype 6B but not serotypes 6A and 6C. Methods. We used a phagocytic killing assay to...

  • Transmission of Streptococcus pneumoniaein Rural Gambian Villages: A Longitudinal Study. Hill, Philip C.; Townend, John; Antonio, Martin; Akisanya, Biodun; Ebruke, Chinelo; Lahai, George; Greenwood, Brian M.; Adegbola, Richard A. // Clinical Infectious Diseases;6/1/2010, Vol. 50 Issue 11, p1468 

    Background. To prepare for national introduction of a pneumococcal vaccine of restricted valency, we studied the pattern of nasopharyngeal carriage of Streptococcus pneumoniae and its transmission in Gambian villages over time. Methods. We collected nasopharyngeal swab specimens every 2 weeks...

  • Increased Penicillin Nonsusceptibility of Nonvaccine-Serotype Invasive Pneumococci Other than Serotypes 19A and 6A in Post-7-Valent Conjugate Vaccine Era. Gertz Jr., Robert E.; Zhongya Li; Pimenta, Fabiana C.; Jackson, Delois; Juni, Billie A.; Lynfield, Ruth; Jorgensen, James H.; da Gloria Carvalho, Maria; Beall, Bernard W. // Journal of Infectious Diseases;3/1/2010, Vol. 201 Issue 5, p770 

    According to population-based invasive pneumococcal surveillance in the United States during 2007, 898 (26%) of 3,511 isolates were penicillin nonsusceptible. Non-7-valent pneumococcal conjugate vaccine (PCV7) serotypes other than 19A accounted for 40% of these penicillin-nonsusceptible...

  • Progress in Introduction of Pneumococcal Conjugate Vaccine -- Worldwide, 2000-2012. Wang, Susan A.; Mantel, Carsten F.; Gacic-Dobo, Marta; Dumolard, Laure; Cherian, Thomas; Flannery, Brendan; Loo, Jennifer D.; Verani, Jennifer R.; Whitney, Cynthia G. // MMWR: Morbidity & Mortality Weekly Report;4/26/2013, Vol. 62 Issue 16, p308 

    The article discusses the progress in the worldwide introduction of pneumococcal conjugate vaccine (PVC) to reduce illness and deaths caused by Streptococcus pneumoniae from 2000-2012. The increase in PCV introductions into national immunization programs was attributed to recommendations for PCV...

  • Literature Reviews: Pediatric Infectious Diseases. Steele, Russell W.; Lampe, John B. // Clinical Pediatrics;Dec1998, Vol. 37 Issue 12, p760 

    Comments on and discusses the abstract of the article `Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants,' by M.B. Rennels, K.M. Edwards, H.L. Keyserling et al taken from the 1998 issue of `Pediatrics'. Streptococcus pneumoniae as most...

  • WHAT'S NEW IN DRUGS.  // RN;Dec79, Vol. 42 Issue 12, p101 

    Presents information on a polyvalent pneumococcal vaccine for the immunization of patients against pneumococci infections. Patients qualified for the vaccine; Infections prevented by the vaccine; Contraindications.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics